Clinical trial
Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.
NCT00276341 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.
- Lead sponsor
- Ipsen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 26, 2003
- Completion date
- December 8, 2005
- Enrollment
- 47 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.